Symbol02257
Company NameSIRNAOMICS-B
ISINKYG2050P1028
Listing DateDec 30, 2021
Issue Price65.90
Shares Offered7.54M share(s)
FoundedOct 15, 2020
Registered AddressCayman Islands
Chairmanyang lu
Secretaryrunting yuan
Audit InstitutionZhonghui Anda Certified Public Accountants Co., Ltd.
Company CategoryOther
Registered OfficePO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business46th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees90
MarketHong Kong motherboard
Phone(852)31809494
Emailinfo-hk@sirnaomics.com
Business Sirnaomics Ltd is an investment holding company. The company and its subsidiaries are clinical-stage biotechnology companies engaged in the development and commercialization of ribonucleic acid interference (RNAi) technology and various therapies. The company is dedicated to the discovery and development of medicines for indications that do not meet medical needs in the region. Its main clinical candidates include STP705 and STP707. Its STP705 is a sterile pharmaceutical product used to treat non-melanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), keloids that recur after keloid resection, hypertrophic scars (HTS), and solid liver tumors, and in medical aesthetics. Its STP707 is a sterile pharmaceutical product used to treat solid tumors, including liver cancer, metastatic cutaneous squamous cell skin cancer (CSCC), and non-small cell lung cancer. It is utilizing its dual delivery platform, which includes polypeptide nanoparticles (PNP) and GalaHead.